MedPath

STANFORD UNIVERSITY

STANFORD UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1885-11-11
Employees
10K
Market Cap
-
Website
http://www.stanford.edu

Clinical Trials

2.0k

Active:79
Completed:1143

Trial Phases

6 Phases

Early Phase 1:34
Phase 1:178
Phase 2:228
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1633 trials with phase data)• Click on a phase to view related trials

Not Applicable
1030 (63.1%)
Phase 2
228 (14.0%)
Phase 1
178 (10.9%)
Phase 4
104 (6.4%)
Phase 3
59 (3.6%)
Early Phase 1
34 (2.1%)

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Not Applicable
Not yet recruiting
Conditions
Medulloblastoma
Central Nervous System Embryonal Tumor
Refractory Medulloblastoma
Recurrent Medulloblastoma
Pediatric Brain Tumor
Interventions
Biological: GPC2-CAR T cells
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Stanford University
Target Recruit Count
18
Registration Number
NCT07087002
Locations
🇺🇸

Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States

🇺🇸

Stanford University, Palo Alto, California, United States

Efficacy of Cervical Sympathetic Blocks for PTSD

Not Applicable
Not yet recruiting
Conditions
PTSD
Interventions
Procedure: Cervical sympathetic nerve block
Procedure: Subcutaneous sham injection
Drug: Normal Saline
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT07087015

Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin

Not Applicable
Conditions
Skin Tear
Solar Purpura
Dermatoporosis
Interventions
Drug: Tretinoin 0.1% cream
Drug: Bland cream (non-drug)
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
Stanford University
Target Recruit Count
30
Registration Number
NCT07084116
Locations
🇺🇸

Palo Alto VA Medical Center, Palo Alto, California, United States

Developing a Digital Aid to Improve ICD Decisions

Not Applicable
Recruiting
Conditions
Heart Failure and Reduced Ejection Fraction
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
Stanford University
Target Recruit Count
120
Registration Number
NCT07084142
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Eastern Carolina University, Greenville, North Carolina, United States

Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome

Not Applicable
Not yet recruiting
Conditions
Idiopathic Hypersomnia
POTS - Postural Orthostatic Tachycardia Syndrome
Interventions
Drug: Low sodium oxybate (LXB)
Drug: Placebo
First Posted Date
2025-07-22
Last Posted Date
2025-07-25
Lead Sponsor
Stanford University
Target Recruit Count
25
Registration Number
NCT07077278
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 406
  • Next

News

Dispatch Bio Emerges with $216M to Develop Universal Solid Tumor Immunotherapy

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

Stanford Researchers Develop Radiation-Free Stem Cell Transplant Protocol for Fanconi Anemia Patients

Stanford Medicine researchers successfully conducted stem cell transplants in three Fanconi anemia patients using the anti-CD117 antibody briquilimab, eliminating the need for toxic radiation or busulfan chemotherapy.

FDA Appoints Biotech Veteran George Tidmarsh to Lead Drug Regulation Center Amid Agency Restructuring

The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research, the agency's largest division responsible for reviewing drug safety and effectiveness.

Fifty1 AI Labs Completes Landmark Phase III REVIVE Trial for Long COVID Treatment

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

Ashvattha Therapeutics Unveils Novel Nanomedicine Radiotracers for Neuroinflammation and Cancer Imaging at SNMMI 2025

Ashvattha Therapeutics will present data on two breakthrough nanomedicine radiotracers at the SNMMI Annual Meeting, demonstrating selective targeting capabilities in neuroinflammation and cancer.

Fujirebio Partners with Stanford Medicine to Advance Ultrasensitive Infectious Disease Diagnostics

Fujirebio has announced a strategic collaboration with Stanford Medicine to accelerate research and innovation in infectious disease testing using ultrasensitive immunoassays.

Stanford Researchers Develop Milli-Spinner Technology That Doubles Blood Clot Removal Effectiveness

Stanford University researchers have developed a breakthrough milli-spinner thrombectomy technology that shrinks blood clots to just 5% of their original volume through a unique rotating mechanism.

FDA Approves First Drug-Free Wearable Device for Pediatric Nasal Congestion Treatment

The FDA has approved an expanded pediatric indication for the SONU Band, making it the first FDA-approved, drug-free solution for nasal congestion and allergies in children aged 12 years and older.

Continuity Biosciences Acquires Focal Medical to Advance Iontophoresis-Based Pancreatic Cancer Therapy

Continuity Biosciences has acquired Focal Medical, a North Carolina-based company developing site-specific chemotherapy using iontophoresis technology for pancreatic cancer treatment.

Matter Neuroscience Partners with Stanford Medicine to Test Novel fMRI-Guided Depression Therapy

Matter Neuroscience has announced a collaboration with Stanford Medicine to conduct a controlled, multi-arm study enrolling at least 210 depressed patients using real-time 7T fMRI neurofeedback combined with the Matter protocol.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.